EICHORPublic-registry site landscape for NCT07680946, “Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia”, a Schizophrenia study sponsored by TG Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07680946 (registry record) |
| Study title | Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia |
| Official title | Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia |
| Sponsor | TG Therapeutics, Inc. |
| Condition(s) | Schizophrenia |
| Phase | PHASE2 |
| Listed sites | 0 |
Patient-friendly overview of this study: eichor.com/study/NCT07680946.
Eichor generates a preliminary site-risk snapshot for NCT07680946 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Schizophrenia trials
More from TG Therapeutics, Inc.
← Eichor home · All tracked trials · Schizophrenia studies · Weekly briefs
